Recently, Pfizer’s new coronavirus treatment drug Paxlovid has received a lot of attention.
is one of the two oral COVID-19 drugs approved by the State Food and Drug Administration. Many consumers are trying their best to buy it from e-commerce platforms and purchasing agents at high prices. Drugs that cost 2,300 yuan per box after using medical insurance can be sold for 8,000 yuan or even tens of thousands of yuan per box through purchasing agents.
In response, the Chinese pharmaceutical company that has obtained the agency rights for Paxlovid in China stated that Paxlovid is a prescription drug and needs to be purchased based on the hospital’s diagnosis and cannot be purchased online.
At the same time, news that Paxlovid has "expired" and is about to enter the Beijing community has also been widely circulated on social platforms. Where can I buy Paxlovid? This is the question that many people are most concerned about right now.
[1] The platform went on sale but was removed from the shelves. Where can I buy Paxlovid?
On December 26, a Paxlovid purchase portal appeared in JD Pharmacy, priced at 2,640 yuan per box. The purchase interface shows that the drug is not open for retail and can only be purchased by nucleic acid or antigen-positive users, and a prescription issued by the fever clinic of the Internet Hospital is required.
Paxlovid on the shelves of JD Pharmacy Source: Blue Whale Financial Reporter Work Platform
Previously, on December 13, Paxlovid, priced at 2,980 yuan/box, was launched on the online platform, and was quickly removed from the shelves.
A consumer once bought Paxlovid on Arkjianke.com for 3,500 yuan per box. The consumer said that he also saw that "1 drug network " was also on sale, priced at 2,980 yuan per box, but the latter was quickly out of stock. The former was also finally shipped nine days after purchase.
At present, the relevant information about the sale of Paxlovid cannot be found through the above channels.
html On the 26th, the securities representative of China Pharmaceutical and Health Industry Co., Ltd. (hereinafter referred to as "China Medicine") stated that the new coronavirus oral drug Paxlovid cannot be purchased through online channels. "Paxlovid is a prescription drug and needs to be purchased based on the hospital's diagnosis." The certificate representative added, "There are state regulations, so it is definitely not available."China Medicine emphasized that you cannot buy Paxlovid online with a doctor's diagnosis. "It is impossible to sell it online now."
As for the domestic price of Paxlovid, some media reported that it is currently 2,980 yuan per box when prescribed by a doctor in the hospital, and 2,300 yuan after using medical insurance. In some purchasing channels, it has been sold for more than 8,000 yuan or even tens of thousands of yuan.
China Medicine stated that the price of Paxlovid is based on the bill issued by the hospital. "Hospital diagnosis is a formal channel and the fee is in compliance with national regulations."
In addition to imported Paxlovid, another new coronavirus oral drug approved by the State Food and Drug Administration is Azivudine tablets , produced by Henan Real Biotechnology. Unlike Paxlovid, Azivudine has been prescribed online. You can prescribe it on multiple Internet diagnosis and treatment platforms based on nucleic acid or antigen results, and the price ranges from more than 300 yuan per box.
[2] It is false news that Paxlovid is about to "expire". Beijing has launched emergency training on drug application.
There are also recent rumors that Paxlovid is about to "expire". On December 26, China Medical Certificate Representative stated that Paxlovid is still within its validity period and it is impossible for the company to sell expired drugs. This behavior does not comply with national regulations.
"At that time, the country emergency approved the marketing of Paxlovid, and the validity period was relatively short, only one year. But this does not mean that we sell expired drugs. This is impossible. The supervision of drugs is very strict, and we cannot sell them if they are about to expire." China Medical Certificate added.
Paxlovid was approved for marketing in China in February this year, and Sinopharm obtained the agency rights in China. Sinopharm announced on December 14 that the company signed an agreement with Pfizer and will be responsible for the import and distribution of Pfizer's new coronavirus treatment drug Nematvir/Ritonavir Tablets (Paxlovid.R) in the Chinese mainland market during the agreement period. The signing and effective date of the agreement is December 14, 2022, Beijing time, and will last until November 30, 2023. Data circulated on the
network shows that Sinopharm’s planned reserve volume from Pfizer is 100,000 boxes, and the customs imported the first batch of 21,200 boxes in early March. Pfizer official website shows that the drug is valid for 18 months.
In addition, there is news that Pfizer Paxlovid may enter the Beijing community.Emergency notices circulating on the Internet show that Beijing will uniformly distribute Paxlovid to various community health service centers in the near future. After community doctors receive training, they will guide COVID-19 patients in their jurisdiction to take it. Emergency training on drug application for community doctors in Beijing was held on the afternoon of December 26.
Picture source Health Times
In response, many community health service centers in Beijing stated that they have received notifications to participate in Paxlovid application training, but the drug is not currently available in the community, and the specific time for the drug to be delivered is not clear.
At the same time, sources said that the National Health Commission had previously organized a "video training session on the use of the anti-new coronavirus drug nematvir/ritonavir tablet combination packaging."
Qichacha APP shows that Pfizer Co., Ltd. has applied for registration of multiple Paxlovid trademarks, of which the medical supplies category has been successfully registered, and the remaining trademark status is under registration application. In addition, many domestic companies, such as Zhejiang Lepu Pharmaceutical Co., Ltd., Astor (Chengdu) Biopharmaceutical Co., Ltd., Hangzhou Guorui Biotechnology Co., Ltd., etc., have disclosed "Paxlovid" related patents.
(Integrated from The Paper News , Daily Economic News , True Stories Research Laboratory, Health Times, China Entrepreneur Magazine, Blue Whale Financial Reporter Work Platform and other media)
Nine Schools of Financial Reporters Huang Mengqi
[Source: Jiupai Finance]
Statement: The copyright of this article belongs to the original author. If there is an error in the source or infringement of your legitimate rights and interests, you can contact us via email and we will handle it in a timely manner. Email address: [email protected]
